PFE pipeline Swim in a big pond if you're 2nd to jump in
We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a
top of page
Recent Research
Aug 28, 2022
BMY/JNJ/BAY: Milvexian moves ahead at ESC
The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...
Aug 14, 2022
Roche: Maintaining Leadership is difficult: nearterm pipeline outlook
We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin...
May 15, 2022
Bayer’s Factor XIa lower bleeding saw more strokes in small trial
We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for
Jan 20, 2017
BMY.US: No Accelerated pathway does not imply registrational failure
Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was...
Oct 27, 2016
AZN.LN: Head and neck hold may explain BMYs hesitance with combo
Head and neck specific? The FDA placed a partial clinical trial hold on recruiting new patients to AstraZeneca’s anti PD-L1 (durvalumab)...
Oct 17, 2016
PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG
Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...
Oct 13, 2016
Unravelling the MYSTICal
Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...
Sep 30, 2016
ESMO 2016: all anti PD1/PDL1 checkpoint inhibitors are not the same
Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s...
Aug 8, 2016
Consensus PD1 hopes under threat
PD1 market continues to shrink, but Bristol’s failure not good news for rivals BMY announced Friday that its pivotal phase III study of...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page